Covid care taskforce sees its funding cut

Press/Media: Expert Comment

Description

Australia’s peak evidence advisory group on Covid-19 treatments has had its funding
discontinued, sparking warnings
there will be “critical gaps” in
doctors’ understanding of the
­efficacy of continually emerging
therapies.
The National Clinical Evidence Taskforce, a union of 35
member organisations that
­includes medical colleges, peak
societies and consumer groups,
was formed at the beginning of
Covid-19 and has been hailed as
“one of the great Australian successes of this pandemic”

Subject

Living guidelines

Covid 19

Period16 Dec 2022

Media contributions

1

Media contributions

  • TitleCovid care taskforce sees its funding cut
    Degree of recognitionNational
    Media name/outletThe Australian
    Media typePrint
    Country/TerritoryAustralia
    Date16/12/22
    DescriptionAustralia’s peak evidence advisory group on Covid-19 treatments has had its funding
    discontinued, sparking warnings
    there will be “critical gaps” in
    doctors’ understanding of the
    ­efficacy of continually emerging
    therapies.
    The National Clinical Evidence Taskforce, a union of 35
    member organisations that
    ­includes medical colleges, peak
    societies and consumer groups,
    was formed at the beginning of
    Covid-19 and has been hailed as
    “one of the great Australian successes of this pandemic”...
    GP Mark Morgan, the cochair of the taskforce’s primary
    and chronic care panel, said the
    Health Department had indic­-
    ated the Pharmaceutical Benefits Advisory Committee and the
    Therapeutic Goods Administration could take over the job of
    analysing new medicines, but the
    taskforce’s work went beyond
    that and was done speedily.
    Producer/AuthorNatasha Robinson
    PersonsMark Morgan